Histological characteristics predisposing to development of hepatocellular carcinoma in patients with chronic hepatitis B

Journal of Clinical Pathology

Volumn 64, Issue 7, 2011, Pages 599-604

  Lee, Sae Hwan ^a   Chung, Young Hwa ^b   Kim, Jeong A ^b   Jin, Young Joo ^b   Park, Won Hyung ^b   Choi, Jong Gi ^b   Lee, Danbi ^b   Shim, Ju Hyun ^b   Yu, Eunsil ^b   Jang, Myoung Kuk ^c  

^a Soonchunhyang University College of Medicine   (South Korea)

^b University of Ulsan College of Medicine   (South Korea)

^c Hallym University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; ALPHA INTERFERON; LAMIVUDINE;

ADULT; AGED; ARTICLE; CHRONIC HEPATITIS; CONTROLLED STUDY; FEMALE; FOLLOW UP; HEPATITIS B; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RETROSPECTIVE STUDY; RISK FACTOR; UNIVARIATE ANALYSIS; X RAY FILM;

ADOLESCENT; ADULT; CARCINOMA, HEPATOCELLULAR; FEMALE; HEPATITIS B, CHRONIC; HUMANS; INCIDENCE; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MIDDLE AGED; RISK FACTORS; YOUNG ADULT;

EID: 79959355995     PISSN: 00219746     EISSN: 14724146     Source Type: Journal    
DOI: 10.1136/jclinpath-2011-200036     Document Type: Article

References (45)

1. Purcell RH. The discovery of the hepatitis viruses. Gastroenterology 1993;104:955-63. (Pubitemid 23090745)
2. Lee WM. Hepatitis B virus infection. N Engl J Med 1997;337:1733-45. (Pubitemid 27527771)
3. Chu CM. Natural history of chronic hepatitis B virus infection in adults with emphasis on the occurrence of cirrhosis and hepatocellular carcinoma. J Gastroenterol Hepatol 2000;15:E25-30.
4. Bosch FX, Ribes J, Diaz M, et al. Primary liver cancer: worldwide incidence and trends. Gastroenterology 2004;127(Supp 1):S5-16.
5. Changchien CS, Chen CL, Yen YH, et al. Analysis of 6381 hepatocellular carcinoma patients in southern Taiwan: prognostic features, treatment outcome, and survival. J Gastroenterol 2008;43:159-70.
6. Cheon JH, Park JW, Park KW, et al. The clinical report of 1,078 cases of hepatocellular carcinomas: national cancer center experience. Korean J Hepatol 2004;10:288-97.
7. Cha C, DeMatteo RP. Molecular mechanisms in hepatocellular carcinoma development. Best Pract Res Clin Gastroenterol 2005;19:25-37. (Pubitemid 40331496)
8. Hino O. Intentional delay of human hepatocarcinogenesis due to suppression of chronic hepatitis. Intervirology 2005;48:6-9. (Pubitemid 40529204)
9. Park NH, Song IH, Chung YH. Chronic hepatitis B in hepatocarcinogenesis. Postgrad Med J 2006;82:507-15. (Pubitemid 44258625)
10. Nakamoto Y, Guidotti LG, Kuhlen CV, et al. Immune pathogenesis of hepatocellular carcinoma. J Exp Med 1998;188:341-50. (Pubitemid 28357762)
11. Coleman WB. Mechanisms of human hepatocarcinogenesis. Curr Mol Med 2003;3:573-88. (Pubitemid 37168599)
12. Yim HJ, Lok AS. Natural history of chronic hepatitis B virus infection: what we knew in 1981 and what we know in 2005. Hepatology 2006;43(Supp 1):S173-81.
13. Brechot C. Pathogenesis of hepatitis B virus - related hepatocellular carcinoma: old and new paradigms. Gastroenterology 2004;127(Supp 1):S56-61.
14. Benvegnu L, Gios M, Boccato S, et al. Natural history of compensated viral cirrhosis: a prospective study on the incidence and hierarchy of major complications. Gut 2004;53:744-9. (Pubitemid 38561455)
15. Giovanna F, Tommaso S, Irene Z, et al. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 2004;127(Supp 1):S35-50.
16. Yu MW, Hsu FC, Sheen IS, et al. Prospective study of hepatocellular carcinoma and liver cirrhosis in asymptomatic chronic hepatitis B virus carriers. Am J Epidemiol 1997;145:1039-47.
17. Fattovich G, Bortolotti F, Donato F. Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J Hepatol 2008;48:335-52.
18. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007;132:2557-76. (Pubitemid 46890874)
19. Park YN, Kim HG, Chon CY, et al. Histological grading and staging of chronic hepatitis standardized guideline proposed by the Korean study group for the pathology of digestive diseases. Korean J Pathol 1999;33:337-46.
20. Bruix J, Sherman M, Llovet JM, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001;35:421-30. (Pubitemid 32844200)
21. Knodell RG, Ishak KG, Black WC, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981;1:431-5. (Pubitemid 12218164)
22. Scheuer PJ. Classification of chronic viral hepatitis: a need for reassessment. J Hepatol 1991;13:372-4.
23. Desmet VJ, Gerber M, Hoofnagle JH, et al. Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology 1994;19:1513-20. (Pubitemid 24166476)
24. Batts KP, Ludwig J. Chronic hepatitis. An update on terminology and reporting. Am J Surg Pathol 1995;19:1409-17.
25. Ishak K, Baptista A, Bianchi L, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995;22:696-9.
26. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. Hepatology 1996;24:289-93. (Pubitemid 26260021)
27. Lefkowitch JH. Liver biopsy assessment in chronic hepatitis. Arch Med Res 2007;38:634-43. (Pubitemid 47001563)
28. Wright TL, Lau JY. Clinical aspects of hepatitis B virus infection. Lancet 1993;342:1340-4. (Pubitemid 23345184)
29. Fattovich G, Brollo L, Giustina G, et al. Natural history and prognostic factors for chronic hepatitis type B. Gut 1991;32:294-8.
30. Ikeda K, Saitoh S, Suzuki Y, et al. Disease progression and hepatocellular carcinogenesis in patients with chronic viral hepatitis: a prospective observation of 2215 patients. J Hepatol 1998;28:930-8. (Pubitemid 28275969)
31. Park BK, Park YN, Ahn SH, et al. Long-term outcome of chronic hepatitis B based on histological grade and stage. J Gastroenterol Hepatol 2007;22:383-8. (Pubitemid 46238769)
32. Lok AS, Ghany MG, Goodman ZD, et al. Predicting cirrhosis in patients with hepatitis C based on standard laboratory tests: results of the HALT-C cohort. Hepatology 2005;42:282-92. (Pubitemid 41061080)
33. Lu SN, Wang JH, Liu SL, et al. Thrombocytopenia as a surrogate for cirrhosis and a marker for the identification of patients at high risk for hepatocellular carcinoma. Cancer 2006;107:2212-22.
34. Wang W, London WT, Feitelson MA. Hepatitis B x antigen in hepatitis B virus carrier patients with liver cancer. Cancer Res 1991;51:4971-77.
35. Koskinas J, Petraki K, Kavantzas N, et al. Hepatic expression of the proliferative marker Ki-67 and p53 protein in HBV or HCV cirrhosis in relation to dysplastic liver cell changes and hepatocellular carcinoma. J Viral Hepatitis 2005;12:635-41. (Pubitemid 41532495)
36. Chen CJ, Yang HI, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006;295:65-73. (Pubitemid 43042691)
37. Yuen MF, Cheng CC, Wu CH, et al. Long-term follow-up of interferon alfa treatment in Chinese patients with chronic hepatitis B infection: the effect on hepatitis B e antigen seroconversion and the development of cirrhosis-related complication. Hepatology 2001;34:139-45.
38. von Zonneveld M, Honkoop P, Hansen BE, et al. Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis B. Hepatology 2004;39:804-10. (Pubitemid 38337661)
39. Lin SM, Yu ML, Lee CM, et al. Interferon therapy in HBeAg positive chronic hepatitis reduces progression to cirrhosis and hepatocellular carcinoma. J Hepatol 2007;46:45-52.
40. Liaw YF, Sung JY, Chow WC, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004;351:1521-31.
41. Okanoue T, Itoh Y, Minami M, et al. Interferon therapy lowers the rate of progression to hepatocellular carcinoma in chronic hepatitis C but not significantly in an advanced stage: a retrospective study in 1148 patients. J Hepatol 1999;30:653-9. (Pubitemid 29151907)
42. Tanaka H, Tsukuma H, Kasahara A, et al. Effect of interferon therapy on the incidence of hepatocellular carcinoma and mortality of patients with chronic hepatitis C: a retrospective cohort study of 738 patients. Int J Cancer 2000;87:741-9. (Pubitemid 30620419)
43. Camma C, Giunta M, Andreone P, et al. Interferon and prevention of hepatocellular carcinoma in viral cirrhosis: an evidence-based approach. J Hepatology 2001;34:593-602. (Pubitemid 32328518)
44. Takimoto M, Ohkoshi S, Ichida T, et al. Interferon inhibits progression of liver fibrosis and reduces the risk of hepatocarcinogenesis in patients with chronic hepatitis C: a retrospective multicenter analysis of 652 patients. Dig Dis Sci 2002;47:170-6. (Pubitemid 34075035)
45. Chan HLY, Hui AY, Wong ML, et al. Genotype C hepatitis B virus infection is associated with an increased risk of hepatocellular carcinoma. Gut 2004;53:1494-8. (Pubitemid 39265273)